首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 非專利藥 > 歐洲非專利藥品及生物學名藥市場的價格及償付趨勢
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

歐洲非專利藥品及生物學名藥市場的價格及償付趨勢

Pricing and Reimbursement Issues for Generics & Biosimilars Markets in Europe

出版商 Frost & Sullivan
出版日期 2006年12月 商品編碼 48391
內容資訊 英文 51 Pages
價格
US $ 6500 Web Access (Regional License)
US $ 7000 Hard Copy & Web Access (Regional License)


歐洲非專利藥品及生物學名藥市場的價格及償付趨勢 是由出版商Frost & Sullivan在2006年12月所出版的。 這份英文市場調查報告書包含51 Pages 價格從美金6500起跳。

目錄

Abstract

This Frost & Sullivan research service titled Pricing and Reimbursement Issues for Generics & Biosimilars Markets in Europe provides a detailed analysis of various issues affecting pricing and reimbursement decisions of generics in Europe. The study includes an overview of cost-containment measures such as reference pricing, parallel trade, generic substitution, patient co-payments and reimbursement. Certain key issues such as the EU accession, the Roche/Bolar provision, data exclusivity and marketing authorisation applications are also discussed.

Table of Contents

1. Executive Summary

  • 1. Executive Summary
    • 1. Executive Summary

2. Glossary of Terms

  • 1. Important Terms
    • 1. Definitions

3. Research Methodology

  • 1. Methodology Of Research
    • 1. The "12 Step" Market Engineering Research Methodology and Process

4. Introduction

  • 1. Overview
    • 1. Market Analysis
    • 2. Scope and Objectives
    • 3. Pricing and Reimbursement
    • 4. The Biosimilars Opportunity

5. Key Trends

  • 1. Pharmaceutical Cost-containment Measures
    • 1. Reference Pricing
    • 2. Parallel Trade
    • 3. Generic Substitution
    • 4. Patient Co-payments and Reimbursement
  • 2. Political/Legal/Regulatory Issues
    • 1. Impact of EU Accession
    • 2. The Roche/Bolar Provision
    • 3. Data Exclusivity and Marketing Authorisation Applications

6. Country-wise Policy Analysis

  • 1. Group I
    • 1. Denmark
    • 2. Germany
    • 3. The Netherlands
    • 4. The United Kingdom
  • 2. Group II
    • 1. Austria
    • 2. Belgium
    • 3. France
    • 4. Italy
    • 5. Portugal
    • 6. Spain
  • 3. Group III
    • 1. Central and Eastern Europe (CEE)

7. Market Participants

  • 1. Market Players
    • 1. List of Generics Market Participants
    • 2. List of Biosimilars Market Participants

8. Strategic Recommendations

  • 1. Recommendations to Market Participants
    • 1. Strategic Suggestions

9. Decision Support Databases

  • 1. DSDs
    • 1. Total Healthcare Expenditure
    • 2. Pharma R&D Expenditure

List of Figures

Chapter 4

  • Generics Market: Market Share of Generics by Value and Volume (Europe), 2004

Chapter 5

  • Generics Market: Country-wise Policy on Generic Substitution (Europe), 2006
  • Generics Market: Average Time Required for Pricing and Reimbursement Approvals (Europe), 2004

Chapter 7

  • Generics Market: List of Key Market Participants (Europe), 2006
  • Biosimilars Market: List of Key Market Participants (Europe), 2006
Back to Top